A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 ...
Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. Newly formed Solstice Oncology has inked an exclusive ...
Clinical neurophysiology examinations include electroencephalography, sleep and vigilance studies, as well as nerve conduction recordings. Interpretation of these recordings is largely taught during ...
Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions] I would now like to turn the conference over to ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio CareDx, Inc. (Nasdaq: CDNA) — The ...
While the drug was safe and improved some biological markers linked to the disease, it did not slow memory or cognitive decline compared to a placebo. HealthDay News — A pill version of semaglutide, ...
Governors of California, Oregon, and Washington announced the alliance in response to recent leadership changes and other actions they say have "undermined" the CDC. HealthDay News — The governors of ...
Artificial intelligence-enabled medical devices with no clinical validation were more likely to be the subject of recalls, according to a study published in JAMA Health Forum. The study, published on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results